GBM

Oncology

Prevalence

3.2 / 100K

Incidence

3.2 / 100K/yr

20 drugs in development·11 companies·6 clinical trials

Drug Pipeline by Phase

Phase 3(1)

Drug	Company
silevertinib in combination with temozolomide	Black Diamond Therapeutics, Inc. (BDTX)

Phase 2(7)

Drug	Company
BDTX-1535	Black Diamond Therapeutics, Inc. (BDTX)
DOC1021	Black Diamond Therapeutics, Inc. (BDTX)
inb-400	IN8BIO, INC. (INAB)
reyobiq	PLUS THERAPEUTICS Inc. (PSTV)
silevertinib	Black Diamond Therapeutics, Inc. (BDTX)
sl-701	STEMLINE THERAPEUTICS INC (STML)
wp1066	Moleculin Biotech, Inc. (MBRX)

Phase 1(7)

Preclinical(3)

BLA Filed(1)

Drug	Company
dcvax-l	NORTHWEST BIOTHERAPEUTICS INC (NWBO)

Phase 2/Phase 3(1)

Drug	Company
Actimab-A	Actinium Pharmaceuticals, Inc. (ATNM)

BioSniper tracks 20 drugs in development for GBM across 11 companies.

There are 6 clinical trials targeting GBM tracked by BioSniper.

The estimated prevalence of GBM is approximately 3.2 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.